Search results for " immunogenicity"

showing 10 items of 11 documents

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice

2018

Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors effica…

0301 basic medicineCancer ResearchLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentProgrammed Cell Death 1 Receptorimmune checkpoint inhibitorDiseaseNSCLCBioinformaticsB7-H1 Antigenimmune checkpoint inhibitorsTranslational Research Biomedical0302 clinical medicineCarcinoma Non-Small-Cell LungPD-1clinical studiesNSCLC; PD-1; PD-L1; biomarkers; cancer immunogenicity; clinical studies; immune checkpoint inhibitors; translational researchMolecular Targeted TherapybiologyImmunogenicityGeneral Medicinecancer immunogenicityOncology030220 oncology & carcinogenesisbiomarkerCytokinesImmunotherapyPD-L1chemical and pharmacologic phenomena03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemPD-L1Biomarkers TumormedicineHumansLung cancerbusiness.industryImmunitybiomarkersCancerImmunotherapymedicine.disease030104 developmental biologytranslational researchTumor EscapeMutationbiology.proteinTumor Escapebusinessclinical studieFuture Oncology
researchProduct

Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against Sporothrix schenckii

2021

Made available in DSpace on 2021-06-25T10:56:14Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-04-01 Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Background: In recent years, there has been great interest in developing molecular adjuvants based on antisense oligonucleotides (ASOs) targeting immunosuppressor pathways with inhibitory effects on regulatory T cells (Tregs) to improve immunogenicity and vaccine efficacy. We aim to evaluate the immunostimulating effect of 2′OMe phosphorothioated Foxp3-targeted ASO in an antifungal adjuvanted recombinant vaccine. Methods: The uptake kinetics of Foxp3 ASO, its cyto-toxicity and its ability to deplete Tregs were evaluated in…

Farmacologiamedicine.medical_treatmentÀcids nucleicschemical and pharmacologic phenomenaCatalysisregulatory T cellslaw.inventionInorganic Chemistrylcsh:Chemistryvaccine immunogenicityImmune systemlawantisensense oligonucleotidemedicineVacunacióPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopySporothrix schenckiibiologybusiness.industryImmunogenicityOrganic ChemistryAntibody titerGeneral MedicineFongs patògensVaccine efficacyComputer Science ApplicationsVaccinationlcsh:Biology (General)lcsh:QD1-999Foxp3ImmunologyRecombinant DNAbiology.proteinAntibody<i>Sporothrix schenckii</i>businessAdjuvantInternational Journal of Molecular Sciences
researchProduct

Medical Research and Innovation

2021

This volume is dedicated to multidisciplinary research at the interface between basic biomedicine and clinical practice. This book guides best practice in the diagnosis and therapy while dealing with difficult-to-treat disorders of yet unclear etiology. Chapters address such disorders as granulomatosis with polyangiitis causing autoimmune-related multiorgan inflammation of blood vessels, increasingly widespread allergy to peanuts, occupational exposure to zinc oxide, and immunogenic responses to pneumococcal and influenza vaccination underlying their preventive effectiveness. Other hot issues deal with the proper use of fluid therapy in the perioperative period and a cognitive decline in lu…

Fluid therapyHealthcare managementPulmonary infectionLow back pain physiotherapyPost-surgery cognitive deficitVaccine immunogenicityNut allergensOccupational zinc exposure
researchProduct

Human Wharton's jelly-derived mesenchymal stem cells express several immunomodulatory molecules both in their naïve state and hepatocyte-like differe…

2011

Wharton’s jelly (WJ), the main constituent of umbilical cord, is a reliable source of mesenchymal stem cells (MSC). WJ-MSC show unique ability in crossing lineage borders. As other extraembryonic mesenchymal populations (placenta and amnionderived cells), WJ-MSC express several immunomodulatory molecules, essential during the initial phases of human development. Indeed, our recent work pointed out the expression of non-classical HLA molecules as HLA-G in such cells, together with a favorable combination of B7 costimulators. Very few data in literature suggest that some of the immune features of the naïve cells are maintained after performing differentiation. The aim of this work was extendi…

Hepatocyte differentiationSettore BIO/16 - Anatomia UmanaImmunogenicityMesenchymal stem cellImmune regulationObstetrics and GynecologyClinical uses of mesenchymal stem cellsBiologyUmbilical cordCell biologymedicine.anatomical_structureReproductive MedicineHepatocyteImmunologyWharton's jellymedicineWharton's jelly mesenchymal stem cells umbilical cord hepatocyte differentiation markers immunogenicity immune regulationDevelopmental BiologyPlacenta
researchProduct

INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)

2021

BackgroundUntil now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).MethodsThe prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety.ResultsThe study enrolle…

MaleCancer ResearchTime Factors2435immunogenicity0302 clinical medicineRisk FactorsNeoplasmsvaccineClinical endpointImmunology and Allergyantibodiesantibodies; immunization; immunogenicity; immunotherapy; neoplasm; vaccination; vaccine1506Prospective Studies030212 general & internal medicineImmune Checkpoint InhibitorsRC254-282Clinical/Translational Cancer ImmunotherapyAged 80 and overIncidenceIncidence (epidemiology)virus diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedVaccinationTreatment OutcomeItalyOncologyInfluenza Vaccines030220 oncology & carcinogenesisMolecular MedicineFemaleimmunotherapyAdultmedicine.medical_specialtyInfluenza vaccineImmunologyVaccine EfficacyimmunizationRisk AssessmentYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineHumansLung cancerAdverse effectAgedPharmacologybusiness.industryCancermedicine.diseasevaccinationImmunizationbusinessneoplasm
researchProduct

Recent Advances in Biotechnological Methods for Wheat Gluten Immunotoxicity Abolishment – a Review

2021

Due to the increasing incidence of gluten intolerance, researchers are focusing on finding ways to eliminate immunotoxicity of wheat, this would allow the use of wheat products for gluten-intolerant consumers. The article reviews recent studies on biotechnological methods to eliminate and reduce the immunogenicity of wheat products. So far, many gluten removal methods have been proposed, but their efficacy levels were quite different. Enzymatic treatment of gluten fragments can be considered the simplest and non-invasive tool to eliminate the toxicity of gliadins and glutenins. For this purpose, various endogenous enzymes derived from cereals, and also those of bacterial, fungal, plant, and…

Nutrition and DieteticsChemistrybusiness.industrynutritional and metabolic diseasesfood and beveragesdetoxified wheatWheat glutenlcsh:TX341-641wheat immunogenicityBiotechnologybusinesslcsh:Nutrition. Foods and food supplyceliac diseasegluten hydrolysisFood SciencePolish Journal of Food and Nutrition Sciences
researchProduct

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

2011

Antineoplastic chemotherapies are particularly efficient when they elicit immunogenic cell death, thus provoking an anticancer immune response. Here we demonstrate that autophagy, which is often disabled in cancer, is dispensable for chemotherapy-induced cell death but required for its immunogenicity. In response to chemotherapy, autophagy-competent, but not autophagy-deficient, cancers attracted dendritic cells and T lymphocytes into the tumor bed. Suppression of autophagy inhibited the release of adenosine triphosphate (ATP) from dying tumor cells. Conversely, inhibition of extracellular ATP-degrading enzymes increased pericellular ATP in autophagy-deficient tumors, reestablished the recr…

Programmed cell deathcells cancer immunogenicity calreticulin exposure hmgb1Antineoplastic AgentsBiologyimmunogenicityNOMicechemistry.chemical_compoundAdenosine TriphosphateImmune systemCell Line TumorNeoplasmsAutophagyExtracellularAnimalsHumanscancerMice Inbred BALB CMultidisciplinaryCell DeathImmunogenicityAutophagyDendritic CellsMice Inbred C57BLhmgb1chemistryCell cultureCancer researchImmunogenic cell deathcellsMitoxantroneCalreticulinAdenosine triphosphatecalreticulin exposure
researchProduct

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by…

medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Targeting the tumor mutanome for personalized vaccination therapy

2012

Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.

next generation sequencingSomatic cellbusiness.industryImmunologyBioinformaticscancer immunogenicityDNA sequencingEpitopeVaccinationOncologyImmunizationIn vivoImmunogenic tumornon-synonymous mutationsCancer researchindividualized therapyImmunology and AllergyMedicinetumor mutationsB16f10 melanomacancer vaccinationbusinessAuthor's ViewOncoImmunology
researchProduct

DEVELOPMENT & QUALIFICATION OF BIOASSAYS FOR THE DETERMINATION OF THE BIOACTIVITY, PREDICTIVE PHARMACOKINETICS AND POTENTIAL IMMUNOGENICITY OF THERAP…

2021

The critical quality attributes of a given biotherapeutic monoclonal antibody (mAb), its molecular characterization, functional assessment and effector function analysis should be defined and profiled in detail during the life cycle of a biotherapeutic drug. In the past, this product characterization was simple and standardized. In today’s complex world of biologics, success demands a more thoughtful approach and drug developers are investing in advanced analytics much earlier in the development process. Indeed, investing in selected sophisticated and state of the art analytics in early developmental phases of a therapeutic monoclonal antibody may mitigate risks by confirming that the drug …

predictive pharmacokineticbioassaybiological activitybiotherapeutic antibodiemethod development and qualificationpotential immunogenicity.
researchProduct